TherapeuticsMD (TXMD) EBIT Margin (2011 - 2026)
TherapeuticsMD's (TXMD) quarterly EBIT Margin came in at 93.9% in Q2 2026, down 2090.0% on a YoY basis from 4.72% in Q2 2025, and up 5.97% quarter-over-quarter from 99.86% in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) EBIT Margin (2011 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported EBIT Margin for 16 consecutive years, with 93.9% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBIT Margin fell 2090.0% year-over-year to 93.9%; the trailing twelve-month figure through Jun 2026 stood at 120.89% (up 2612.0% YoY), and the FY2025 full-year result was 145.27%, up 20181.0% from the prior year.
- EBIT Margin improved to 93.9% in Q2 2026 per TXMD's latest filing, from 99.86% in the prior quarter.
- Across five years, EBIT Margin topped out at 70.65% in Q4 2022 and bottomed at 4269.25% in Q2 2022.
- Historically, EBIT Margin has averaged 1026.84% across 5 years, with a median of 323.44% in 2025.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin tumbled 411631 bps in 2022, then soared 370358 bps in 2023.
- Over 5 years, EBIT Margin stood at 70.65% in 2022, then sank by 554 bps to 320.92% in 2023, then jumped by 70 bps to 97.75% in 2024, then sank by 78 bps to 173.8% in 2025, then jumped by 46 bps to 93.9% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 93.9%, 99.86%, and 173.8% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 28.37% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 2.77% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 9.03% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 19.06% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | -93.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -93.90% |
| Mar 31, 2026 | -99.86% |
| Dec 31, 2025 | -173.80% |
| Sep 30, 2025 | -109.95% |
| Jun 30, 2025 | -73.00% |
| Mar 31, 2025 | -325.95% |
| Dec 31, 2024 | -97.75% |
| Sep 30, 2024 | -207.31% |
| Jun 30, 2024 | -1,191.88% |
| Mar 31, 2024 | -364.86% |
| Dec 31, 2023 | -320.92% |
| Sep 30, 2023 | -3,345.28% |
| Jun 30, 2023 | -565.68% |
| Mar 31, 2023 | -641.11% |
| Dec 31, 2022 | 70.65% |
| Sep 30, 2022 | -4,101.41% |
| Jun 30, 2022 | -4,269.25% |
| Mar 31, 2022 | -2,571.94% |
| Dec 31, 2021 | -189.48% |
| Sep 30, 2021 | -157.13% |